ES2868074T3 - Métodos para unir adaptadores a ácidos nucleicos de muestra - Google Patents
Métodos para unir adaptadores a ácidos nucleicos de muestra Download PDFInfo
- Publication number
- ES2868074T3 ES2868074T3 ES18783709T ES18783709T ES2868074T3 ES 2868074 T3 ES2868074 T3 ES 2868074T3 ES 18783709 T ES18783709 T ES 18783709T ES 18783709 T ES18783709 T ES 18783709T ES 2868074 T3 ES2868074 T3 ES 2868074T3
- Authority
- ES
- Spain
- Prior art keywords
- adapters
- nucleic acids
- stranded
- sample
- polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 134
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 125
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 125
- 238000000034 method Methods 0.000 title claims abstract description 73
- 239000002773 nucleotide Substances 0.000 claims abstract description 85
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 85
- 230000000694 effects Effects 0.000 claims abstract description 28
- 238000012360 testing method Methods 0.000 claims abstract description 23
- 108090000790 Enzymes Proteins 0.000 claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 claims abstract description 20
- 238000004458 analytical method Methods 0.000 claims abstract description 12
- 230000009471 action Effects 0.000 claims abstract description 6
- 230000000295 complement effect Effects 0.000 claims abstract description 6
- 108020004414 DNA Proteins 0.000 claims description 85
- 206010028980 Neoplasm Diseases 0.000 claims description 52
- 238000012163 sequencing technique Methods 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 26
- 102000053602 DNA Human genes 0.000 claims description 19
- 230000003321 amplification Effects 0.000 claims description 15
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 15
- 210000001124 body fluid Anatomy 0.000 claims description 12
- 239000010839 body fluid Substances 0.000 claims description 12
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 238000007481 next generation sequencing Methods 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 7
- 108010006785 Taq Polymerase Proteins 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 108010017826 DNA Polymerase I Proteins 0.000 claims description 3
- 102000004594 DNA Polymerase I Human genes 0.000 claims description 3
- 230000000392 somatic effect Effects 0.000 claims description 3
- 239000000523 sample Substances 0.000 description 97
- 102000040430 polynucleotide Human genes 0.000 description 28
- 108091033319 polynucleotide Proteins 0.000 description 28
- 239000002157 polynucleotide Substances 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 20
- 239000012634 fragment Substances 0.000 description 18
- 201000010099 disease Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000000203 mixture Substances 0.000 description 11
- 238000012545 processing Methods 0.000 description 11
- 238000009826 distribution Methods 0.000 description 10
- 230000035772 mutation Effects 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 102000013165 exonuclease Human genes 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000007614 genetic variation Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000000439 tumor marker Substances 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 238000007259 addition reaction Methods 0.000 description 2
- 208000036878 aneuploidy Diseases 0.000 description 2
- 231100001075 aneuploidy Toxicity 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- -1 rRNA Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000037439 somatic mutation Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000010505 Nose Neoplasms Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108091046869 Telomeric non-coding RNA Proteins 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000006154 adenylylation Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000001726 chromosome structure Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007672 fourth generation sequencing Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 210000003731 gingival crevicular fluid Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000002679 microRNA Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007480 sanger sequencing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1065—Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
- C12Q1/6855—Ligating adaptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/191—Modifications characterised by incorporating an adaptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2533/00—Reactions characterised by the enzymatic reaction principle used
- C12Q2533/10—Reactions characterised by the enzymatic reaction principle used the purpose being to increase the length of an oligonucleotide strand
- C12Q2533/107—Probe or oligonucleotide ligation
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762485769P | 2017-04-14 | 2017-04-14 | |
| PCT/US2017/027809 WO2017181146A1 (en) | 2016-04-14 | 2017-04-14 | Methods for early detection of cancer |
| US201762486663P | 2017-04-18 | 2017-04-18 | |
| US201762517145P | 2017-06-08 | 2017-06-08 | |
| PCT/US2018/027632 WO2018191702A2 (en) | 2017-04-14 | 2018-04-13 | Methods of attaching adapters to sample nucleic acids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2868074T3 true ES2868074T3 (es) | 2021-10-21 |
Family
ID=63792821
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18783709T Active ES2868074T3 (es) | 2017-04-14 | 2018-04-13 | Métodos para unir adaptadores a ácidos nucleicos de muestra |
| ES21157081T Active ES2962223T3 (es) | 2017-04-14 | 2018-04-13 | Métodos para unir adaptadores a ácidos nucleicos de muestra |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES21157081T Active ES2962223T3 (es) | 2017-04-14 | 2018-04-13 | Métodos para unir adaptadores a ácidos nucleicos de muestra |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200131567A1 (https=) |
| EP (2) | EP3610032B1 (https=) |
| JP (2) | JP7046097B2 (https=) |
| CN (1) | CN110546272B (https=) |
| AU (1) | AU2018252018A1 (https=) |
| CA (1) | CA3057163A1 (https=) |
| ES (2) | ES2868074T3 (https=) |
| HU (1) | HUE063675T2 (https=) |
| PL (1) | PL3885445T3 (https=) |
| WO (1) | WO2018191702A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4293125A3 (en) | 2012-12-10 | 2024-02-28 | Resolution Bioscience, Inc. | Methods for targeted genomic analysis |
| US20160053301A1 (en) | 2014-08-22 | 2016-02-25 | Clearfork Bioscience, Inc. | Methods for quantitative genetic analysis of cell free dna |
| RU2018121254A (ru) | 2015-11-11 | 2019-12-16 | Резолюшн Байосайенс, Инк. | Высокоэффективное построение библиотек днк |
| EP4488686A3 (en) | 2016-04-14 | 2025-04-30 | Guardant Health, Inc. | Methods for early detection of cancer |
| US11319594B2 (en) | 2016-08-25 | 2022-05-03 | Resolution Bioscience, Inc. | Methods for the detection of genomic copy changes in DNA samples |
| CN116144735A (zh) * | 2019-08-12 | 2023-05-23 | 深圳市真迈生物科技有限公司 | 核酸样本处理方法、测序方法和试剂盒 |
| US11891653B2 (en) * | 2019-09-30 | 2024-02-06 | Guardant Health, Inc. | Compositions and methods for analyzing cell-free DNA in methylation partitioning assays |
| US11447819B2 (en) * | 2019-10-25 | 2022-09-20 | Guardant Health, Inc. | Methods for 3′ overhang repair |
| WO2022055984A1 (en) * | 2020-09-08 | 2022-03-17 | Resolution Bioscience, Inc. | Adaptors and methods for high efficiency construction of genetic libraries and genetic analysis |
| JP2023551072A (ja) | 2020-11-25 | 2023-12-06 | アリダ・バイオサイエンシーズ・インコーポレイテッド | Ｒｎａおよびｄｎａ修飾の多重プロファイリング |
| JPWO2022131285A1 (https=) * | 2020-12-15 | 2022-06-23 | ||
| EP4388091A2 (en) * | 2021-08-20 | 2024-06-26 | Guardant Health, Inc. | Methods for simultaneous molecular and sample barcoding |
| WO2023097295A1 (en) | 2021-11-24 | 2023-06-01 | Alida Biosciences, Inc. | Rna and dna analysis using engineered surfaces |
| KR20250175336A (ko) * | 2023-04-21 | 2025-12-16 | 트위스트 바이오사이언스 코포레이션 | 중합효소 변이체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6582908B2 (en) | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
| US20030017081A1 (en) | 1994-02-10 | 2003-01-23 | Affymetrix, Inc. | Method and apparatus for imaging a sample on a device |
| AU2002359522A1 (en) | 2001-11-28 | 2003-06-10 | Applera Corporation | Compositions and methods of selective nucleic acid isolation |
| US8835358B2 (en) | 2009-12-15 | 2014-09-16 | Cellular Research, Inc. | Digital counting of individual molecules by stochastic attachment of diverse labels |
| WO2011161549A2 (en) * | 2010-06-24 | 2011-12-29 | Population Genetics Technologies Ltd. | Methods and compositions for polynucleotide library production, immortalization and region of interest extraction |
| US8829172B2 (en) | 2011-03-11 | 2014-09-09 | Academia Sinica | Multiplex barcoded paired-end diTag (mbPED) sequencing approach and ITS application in fusion gene identification |
| US10023856B2 (en) * | 2013-09-25 | 2018-07-17 | Thermo Fisher Scientific Baltics Uab | Enzyme composition for DNA end repair, adenylation, phosphorylation |
| CA2935122C (en) | 2013-12-30 | 2023-09-19 | Atreca, Inc. | Analysis of nucleic acids associated with single cells using nucleic acid barcodes |
| CA2956925C (en) * | 2014-08-01 | 2024-02-13 | Dovetail Genomics, Llc | Tagging nucleic acids for sequence assembly |
| WO2016135300A1 (en) * | 2015-02-26 | 2016-09-01 | Qiagen Gmbh | Efficiency improving methods for gene library generation |
-
2018
- 2018-04-13 ES ES18783709T patent/ES2868074T3/es active Active
- 2018-04-13 CA CA3057163A patent/CA3057163A1/en active Pending
- 2018-04-13 HU HUE21157081A patent/HUE063675T2/hu unknown
- 2018-04-13 EP EP18783709.1A patent/EP3610032B1/en active Active
- 2018-04-13 CN CN201880025117.1A patent/CN110546272B/zh active Active
- 2018-04-13 JP JP2019555645A patent/JP7046097B2/ja active Active
- 2018-04-13 PL PL21157081.7T patent/PL3885445T3/pl unknown
- 2018-04-13 AU AU2018252018A patent/AU2018252018A1/en not_active Abandoned
- 2018-04-13 EP EP21157081.7A patent/EP3885445B1/en active Active
- 2018-04-13 ES ES21157081T patent/ES2962223T3/es active Active
- 2018-04-13 WO PCT/US2018/027632 patent/WO2018191702A2/en not_active Ceased
-
2019
- 2019-10-08 US US16/596,180 patent/US20200131567A1/en not_active Abandoned
-
2020
- 2020-05-21 US US16/880,706 patent/US20200283839A1/en not_active Abandoned
-
2022
- 2022-02-04 JP JP2022016339A patent/JP7514263B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3610032B1 (en) | 2021-03-10 |
| CN110546272A (zh) | 2019-12-06 |
| EP3885445A1 (en) | 2021-09-29 |
| EP3610032A4 (en) | 2020-05-06 |
| US20200131567A1 (en) | 2020-04-30 |
| PL3885445T3 (pl) | 2024-01-29 |
| US20200283839A1 (en) | 2020-09-10 |
| JP2020516281A (ja) | 2020-06-11 |
| JP7514263B2 (ja) | 2024-07-10 |
| CN110546272B (zh) | 2024-06-07 |
| ES2962223T3 (es) | 2024-03-18 |
| WO2018191702A2 (en) | 2018-10-18 |
| HUE063675T2 (hu) | 2024-01-28 |
| EP3610032A2 (en) | 2020-02-19 |
| JP2022048389A (ja) | 2022-03-25 |
| WO2018191702A3 (en) | 2019-02-21 |
| EP3885445B1 (en) | 2023-08-23 |
| JP7046097B2 (ja) | 2022-04-01 |
| AU2018252018A1 (en) | 2019-10-10 |
| CA3057163A1 (en) | 2018-10-18 |
| EP3885445C0 (en) | 2023-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2868074T3 (es) | Métodos para unir adaptadores a ácidos nucleicos de muestra | |
| US20210207207A1 (en) | Methods for next generation genome walking and related compositions and kits | |
| ES2925014T3 (es) | Identificación y uso de ácidos nucleicos circulantes | |
| ES2769241T5 (es) | Sistemas y métodos para detectar variación en el número de copias | |
| TW202012638A (zh) | 用於癌症及贅瘤之評估的組合物及方法 | |
| KR101858344B1 (ko) | 바코드 서열을 포함하는 어댑터를 이용한 차세대 염기서열 분석 방법 | |
| US12365940B2 (en) | Methods of labelling nucleic acids using variable length oligonucleotides | |
| CN110741096A (zh) | 用于检测循环肿瘤dna的组合物和方法 | |
| US20240002922A1 (en) | Methods for simultaneous molecular and sample barcoding | |
| WO2023018944A1 (en) | Methods for simultaneous mutation detection and methylation analysis | |
| ES2971348T3 (es) | Métodos de reparación de salientes 3' | |
| ES3020408T3 (en) | Multifunctional primers for paired sequencing reads | |
| JP2026067857A (ja) | ３’オーバーハングを修復する方法 |